TMEM235: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: TMEM235

NCBI ID: G283999

TMEM235

TMEM235: A Potential Drug Target Or Biomarker for Various Diseases

TMEM235 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The gene is located on chromosome 16 and has been shown to play a role in the development and progression of these diseases.

The TMEM235 gene is a member of the transmembrane protease serine (TMES) family, which is known for their role in the regulation of cell signaling pathways. TMES proteins are involved in the formation of the outer membrane of cells and play a key role in the regulation of cell survival and survival signaling pathways.

The TMEM235 gene was first identified in 2008 as a potential gene that could be targeted for therapeutic intervention. Studies have shown that TMEM235 is expressed in a variety of tissues and cells, including brain, spinal cord, and peripheral tissues, and is involved in the development and progression of various diseases.

One of the key features of TMEM235 is its role in the development of neurodegenerative disorders. neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These disorders include Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Studies have shown that TMEM235 is involved in the development and progression of neurodegenerative disorders by contributing to the neurofibrillary tangles and the loss of brain cells that occur in these disorders. Additionally, the gene has been shown to be involved in the regulation of neurotransmitter signaling pathways, which are critical for the function of brain cells.

Another potential drug target for TMEM235 is its role in the development and progression of cancer. Cancer is a group of diseases that are characterized by the uncontrolled growth and spread of cells. TMEM235 has been shown to be involved in the regulation of cell signaling pathways, which are critical for the growth and survival of cancer cells.

Studies have shown that TMEM235 is involved in the regulation of multiple signaling pathways that are critical for the growth and survival of cancer cells. Additionally, the gene has been shown to be involved in the regulation of cell apoptosis, which is the process by which cancer cells die and are removed from the body.

In addition to its potential drug target properties, TMEM235 has also been shown to be a potential biomarker for the diagnosis and prognosis of various diseases. The gene has been shown to be involved in the regulation of cell signaling pathways, which are critical for the function of many tissues and organs.

Studies have shown that TMEM235 is involved in the regulation of a variety of signaling pathways, including those that are involved in cell growth, survival, and angiogenesis. Additionally, the gene has been shown to be involved in the regulation of inflammation, which is a critical factor in the development of many diseases.

Overall, TMEM235 is a gene that has the potential to be a drug target or biomarker for the treatment of a variety of diseases. Further research is needed to fully understand the role of TMEM235 in these diseases and to develop effective treatments.

Protein Name: Transmembrane Protein 235

The "TMEM235 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM235 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets